| metastatic/adv melanoma (mML) | |||||||
| mML - NA - all population | mML - NA - PDL1 positive | mML - L1 - all population | mML - L1 - BRAF mutant | mML - L1 - BRAF wild | mML - L2 - all population | mML - L2 - BRAF mutant | |
| anti-PD-(L)1 | |||||||
| atezolizumab based treatment | |||||||
| atezolizumab plus cometinib | IMspire-170 | ||||||
| atezolizumab plus SoC | IMspire-150 ... | ||||||
| nivolumab based treatment | |||||||
| nivolumab alone | CheckMate 238 IMMUNED ... | CheckMate 067 ... | CheckMate 066 | CheckMate 037 | |||
| nivolumab followed by ipilimumab | CheckMate 064 | ||||||
| pembrolizumab based treatment | |||||||
| pembrolizumab alone | KEYNOTE 054 ... | KEYNOTE 054 ... | |||||
| pembrolizumab (10mg/kg) | KEYNOTE-006 ... KEYNOTE-002 ... | ||||||
| pembrolizumab (10mg/kg) 2 weeks | KEYNOTE-006 ... | ||||||
| pembrolizumab (2mg/kg) | KEYNOTE-002 ... | ||||||
| pembrolizumab plus SoC | KEYNOTE-022 | ||||||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
